GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (FRA:NXE0) » Definitions » Cyclically Adjusted Price-to-FCF

Seelos Therapeutics (FRA:NXE0) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Seelos Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Seelos Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Seelos Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics Cyclically Adjusted Price-to-FCF Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Seelos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Seelos Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Seelos Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Seelos Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Seelos Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Seelos Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.627/131.7762*131.7762
=-2.627

Current CPI (Mar. 2024) = 131.7762.

Seelos Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -3,463.000 100.560 -4,538.020
201409 -3,217.000 100.428 -4,221.182
201412 -7,460.000 99.070 -9,922.816
201503 -5,813.000 99.621 -7,689.285
201506 -7,692.000 100.684 -10,067.375
201509 -5,900.000 100.392 -7,744.476
201512 -1,314.000 99.792 -1,735.141
201603 -5,631.000 100.470 -7,385.576
201606 -2,892.000 101.688 -3,747.703
201609 -767.000 101.861 -992.258
201612 -2,564.000 101.863 -3,316.957
201703 -2,521.000 102.862 -3,229.639
201706 -1,009.500 103.349 -1,287.172
201709 -1,270.000 104.136 -1,607.095
201712 -1,045.000 104.011 -1,323.956
201803 -782.000 105.290 -978.720
201806 -553.667 106.317 -686.252
201809 176.923 106.507 218.899
201812 -1,526.250 105.998 -1,897.428
201903 -189.919 107.251 -233.349
201906 -33.943 108.070 -41.389
201909 -26.158 108.329 -31.820
201912 -40.761 108.420 -49.542
202003 -40.937 108.902 -49.536
202006 -33.690 108.767 -40.817
202009 -18.107 109.815 -21.728
202012 -12.214 109.897 -14.646
202103 -32.819 111.754 -38.699
202106 -20.114 114.631 -23.122
202109 -20.972 115.734 -23.879
202112 -37.483 117.630 -41.991
202203 -35.175 121.301 -38.213
202206 -43.652 125.017 -46.012
202209 -25.135 125.227 -26.450
202212 -27.644 125.222 -29.091
202303 -20.608 127.348 -21.325
202306 -9.907 128.729 -10.142
202309 -8.731 129.860 -8.860
202312 -2.021 129.419 -2.058
202403 -2.627 131.776 -2.627

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Seelos Therapeutics  (FRA:NXE0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Seelos Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Seelos Therapeutics (FRA:NXE0) Business Description

Traded in Other Exchanges
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.

Seelos Therapeutics (FRA:NXE0) Headlines

No Headlines